What are the various types of insulin and their clinical uses?

Types of Insulin and Their Clinical Uses

Insulin therapy encompasses rapid-acting analogs (lispro, aspart, glulisine), ultra-rapid formulations (faster aspart, ultra-rapid lispro), short-acting human regular insulin, intermediate-acting NPH, long-acting basal insulins (glargine, detemir, degludec), premixed combinations, concentrated formulations (U-200, U-300, U-500), and inhaled technosphere insulin, each designed to address specific glycemic patterns in diabetes management. 1, 2

Basal Insulins

Basal insulins provide constant background insulin coverage throughout the day and night:

• Long-acting analogs include insulin glargine (available as U-100 and U-300 concentrations) and insulin degludec (U-100 and U-200), which offer flat activity profiles with lower hypoglycemia risk compared to NPH insulin 1, 3
• U-300 glargine has a longer duration of action than U-100 glargine but modestly lower efficacy per unit administered 1
• Insulin degludec has a mean half-life of 25.4 hours with duration exceeding 42 hours and demonstrates lower nocturnal hypoglycemia rates than glargine, allowing flexible once-daily dosing 3
• Insulin detemir consistently produces less weight gain than NPH insulin while maintaining good clinical efficacy 3
• Intermediate-acting NPH remains a cost-effective option, though with higher hypoglycemia risk and greater variability 1, 4

Prandial (Mealtime) Insulins

Prandial insulins control postprandial glucose excursions:

• Rapid-acting analogs (lispro, aspart, glulisine) have amino acid modifications enabling faster subcutaneous absorption with onset within 15 minutes, allowing injection just before meals 2, 3
• Ultra-rapid analogs (faster aspart, ultra-rapid lispro) provide even shorter onset of action with better mealtime flexibility 2, 5
• Human regular insulin has slower onset and extended duration (4-6 hours), potentially causing post-meal hyperglycemia and delayed hypoglycemia, making it less ideal for prandial coverage 2, 4
• Inhaled technosphere insulin offers an alternative delivery route for prandial coverage with very rapid action 2, 5

Premixed/Biphasic Insulins

Premixed formulations combine rapid-acting and intermediate-acting components:

• Premixed analogs contain a proportion of protaminated rapid-acting insulin, providing both immediate and intermediate coverage in one injection 3
• NPH/regular combinations (such as 70/30 formulations) represent cost-effective alternatives to analog premixes 1
• Two daily doses of premixed insulin offer a simple, convenient approach for spreading insulin coverage across the day, particularly useful when administering multiple daily injections is not feasible 1

Concentrated Insulin Formulations

Concentrated insulins reduce injection volume for patients requiring high doses:

• U-500 regular insulin is five times more concentrated than U-100, with pharmacokinetics resembling premixed NPH/regular insulin, used as 2-3 daily injections in highly insulin-resistant patients 1
• U-500 requires dedicated U-500 syringes when using vials to prevent potentially fatal dosing errors 1
• U-200 formulations (degludec, lispro, lispro-aabc) have pharmacokinetics similar to U-100 counterparts 1
• Concentrated insulins except U-500 are available only in prefilled pens to minimize dosing errors 1

Clinical Application Strategies

Basal-Bolus Regimens

• Start prandial insulin with 4 units or 10% of basal dose at the largest meal, advancing to multiple doses as needed 1
• Basal-bolus plans offer flexibility for irregular eating schedules and variable meal content 1
• When adding significant prandial doses, particularly at dinner, reduce basal insulin to prevent hypoglycemia 1

GLP-1 RA Integration

• Before intensifying to prandial insulin, consider adding GLP-1 RA (as individual product or fixed-ratio combination with basal insulin) to address prandial management while reducing hypoglycemia and weight gain risks 1

Special Populations

• Pregnancy: Human regular insulin, aspart, lispro, and faster aspart are recommended options 2
• Type 2 diabetes patients generally require higher daily doses (≥1 unit/kg) due to greater insulin resistance 1
• Patients requiring ≥60 units daily may benefit from basal/bolus/correctional regimens over basal/correctional alone for improved glycemic control 6

Critical Pitfall: Postprandial Control

Achieving HbA1c <7.0% requires strict postprandial glucose control across all diabetes subphenotypes, as self-monitored PPG consistently exceeds 140 mg/dL (7.8 mmol/L) in non-responders despite adequate fasting glucose control 7. This emphasizes that optimizing basal insulin alone is insufficient—appropriate prandial coverage is essential for glycemic targets.

Delivery Systems

• Continuous insulin pumps (programmable automated or fixed settings) and bolus-only patch pumps provide alternative subcutaneous delivery methods 1
• Automated insulin delivery systems represent standard of care outside pregnancy, improving time in range with lower hypoglycemia risk 8

Human regular insulin and NPH remain valuable cost-effective alternatives when analog insulins are financially prohibitive, though they require more careful timing and carry higher hypoglycemia risk 1, 4.